In this issue:
Atorvastatin for GVHD prevention in SCT donors and recipients
Leukaemia selection
Allogeneic SCT with RIC following FLAMSA for refractory/relapsed AML
Azacitidine and gemtuzumab in older patients with AML
Lymphoma selection
Rituximab vs. observation after R-FND in elderly advanced FL
Lenalidomide in MCL after bortezomib failure
Low-intensity therapy in Burkitt’s lymphoma
Autologous SCT as consolidation for aggressive non-Hodgkin’s lymphoma
Enhanced IPI for DLBCL in the rituximab era
Breast implant-associated anaplastic large-cell lymphoma
Please login below to download this issue (PDF)